Listen to lung cancer experts Edward S. Kim, MD, FACP, and Leora Horn, MD, MSc, FRCPC, answer audience questions from a live CCO Webinar on biomarker testing and selecting targeted therapies for patients with advanced NSCLC.
In this podcast episode, listen to lung cancer experts Edward S. Kim, MD, FACP, and Leora Horn, MD, MSc, FRCPC, answer audience questions from a live CCO Webinar on the topic of current and evolving biomarkers for immune checkpoint inhibitor–based therapies in advanced NSCLC.
In this pocast episode, listen to Helena A. Yu, MD, a medical oncologist, and Maria E. Arcila, MD, a molecular pathologist, discuss new data on actionable mutations and targeted therapies in NSCLC from ESMO 2020, including emerging therapeutic strategies targeting EGFR or KRAS G12C driver mutations.
In this podcast episode, listen to Nathan Pennell, MD, PhD, a medical oncologist, and Laura J. Tafe, MD, a molecular pathologist, as they answer questions from a clinician audience on best practices when testing for actionable mutations in NSCLC.
Key insights from our podcast featuring expert answers to questions on biomarker testing and selecting targeted therapies for patients with advanced NSCLC.
Highlights from our podcast featuring expert answers to questions on current and evolving biomarkers for immune checkpoint inhibitor–based therapies in patients with advanced NSCLC.
Highlights from our podcast featuring a medical oncologist and molecular pathologist discussing key data from ESMO 2020 informing precision medicine in NSCLC.
Highlights from our podcast featuring a medical oncologist and molecular pathologist discussing best practices when testing for actionable biomarkers in NSCLC.
Watch this on-demand Webcast capturing a live CCO Webinar featuring expert presentations on new and emerging molecular targets guiding lung cancer management, from the role of biomarkers in immunotherapy to insights on NTRK fusions, RET fusions, and MET exon 14–skipping mutations.
Watch this on-demand Webcast capturing a live CCO Webinar featuring expert perspectives from a medical oncologist and molecular pathologist on biomarker testing and personalized therapy in lung cancer.
Download these slides to review expert insights from a medical oncologist on established and emerging biomarkers critical to optimal use of targeted therapy and immunotherapy in patients with NSCLC.
Download these slides to review expert insights from a pathologist on best practices for biomarker testing in the treatment of patients with advanced NSCLC.
Download this short summary slideset of key takeaway points from a live CCO meeting series on the evolving use of biomarkers for precision therapy in lung cancer.
Download this short summary slideset of key takeaways from a live CCO Webinar focused on the use of new biomarkers critical to lung cancer care today.
Download this short summary slideset of key takeaways from a live CCO Webinar featuring a medical oncologist and molecular pathologist discussing established and emerging biomarkers critical to optimal treatment of patients with advanced NSCLC.
Download these slides from our live meeting series to gain expert insights on how to integrate new and emerging molecular targets into the care of your patients with lung cancer.
Download this slideset on new and emerging molecular targets critical to lung cancer care, including expert insight on NTRK fusions, RET fusions, and MET exon 14 skipping mutations.
Download this slideset for expert insights on the role of biomarkers in the optimal use of immunotherapy in the care of patients with NSCLC.
Which emerging biomarkers have the most potential to affect personalized care of our patients with NSCLC? Read my thoughts on testing for and targeting RET, MET exon 14, and more.
As targeted therapy prolongs survival in our patients with oncogene-driven NSCLC, CNS metastases and leptomeningeal carcinomatosis are more likely to develop as part of the disease course. Read my thoughts on what factors I consider when treating these challenging disease manifestations.
Vamsidhar Velcheti, MD, provides his thoughts on the clinical implications of the recent approval of selpercatinib for RET fusion–positive NSCLC in this commentary.
Are you aware of emerging options for the treatment of advanced HER2-mutated NSCLC? Read my thoughts on a new therapy showing promise to improve outcomes in these patients.
Download this PDF resource for clinical insights on new and established clinical biomarkers guiding NSCLC management, including best testing practices.
Use this Interactive Decision Support Tool to compare your choice of therapy for patients with NSCLC with those of 5 renowned experts.
Contact Clinical Care Options
For customer support please email: customersupport@cealliance.com
Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.